What's new
Everything that changed here, newest first: research, patents, portfolio works, books, and the site itself.
September 2026
NewResearch & IP
Typed Utterances and Honest Uncertainty
Every statement the system makes carries a type: observation, inference, recommendation, automated action, human-approved action, unresolved uncertainty, or prohibited action. Missing data is rendered as missing, and standing constraints hold at every autonomy level.
NewResearch & IP
What is actually medically specialized
Separate component availability from medical performance. The part being cheap says nothing about calibration, accuracy, reliability, safety, cybersecurity, manufacturing controls, or evidence. Confusing the two is how consumer-grade thinking hurts patients.
NewResearch & IP
What This Line of Research Does Not Claim
No proven outcome improvement without a connected analytics warehouse; disagreement concentrating in recent medication changes; projections that remain projections. The limits stated plainly, in one place.
NewResearch & IP
Where the device thesis should be rejected
The rejection criteria, written before we get attached to anything. Novel materials, exotic sensing physics, sterile manufacturing, life-sustaining risk, and trial-scale evidence requirements all put a category outside this thesis.
NewResearch & IP
Adoption latency score
Estimate the time from first evidence to first use, repeat use, and routine use without pretending institutional clocks disappear.
NewResearch & IP
Adversarial design-around report
Give a capable future competitor the customer outcome and ask for credible routes around the proposed boundary.
NewResearch & IP
AI changes the configuration economics
Specialized SaaS won largely because configuring general-purpose platforms was expensive. If AI collapses that cost, the reason for the historical result stops applying.
NewResearch & IP
AI compression test
Assume capable AI makes ordinary reasoning and software cheap, then identify how much of the claimed advantage disappears.
NewResearch & IP
AI resilience score
Test what remains scarce after a competitor gains better models, tools, and engineering capacity.
NewResearch & IP
Alpha to Operate dependency and rights map
Map the rights owned and the rights still needed to build, sell, deploy, manufacture, distribute, or license a product wedge.
NewResearch & IP
Alpha to Rights decision memo
Match each scarce asset to the narrowest control that can protect and commercialize it.
NewResearch & IP
An AI credential
Represent trust as evidence about a narrow capability, approved sources, authority, incidents, and recertification.
NewResearch & IP
Authority progression and recertification
Increase authority only after evidence and reduce it automatically when material conditions change.
NewResearch & IP
Burden Payer and Burden Imposer matrix
Show who requires work, who performs it, who pays, who benefits, who waits, and who can change it.
NewResearch & IP
Capability Formation map
Identify which repeated work creates future judgment and replace that learning path before automation removes it.
NewResearch & IP
Care delivery opportunity screen
Test whether patient access, workflow control, payment, outcomes, technology absorption, and learning support a care business.
NewResearch & IP
Care delivery readiness map
A review of patient, caregiver, clinician, site, supply, data, payment, and exception readiness before an intervention enters routine care.
NewResearch & IP
Care model decision package
Bring the hypothesis, evidence, economics, rights, uncertainty, failure case, and next decision into one reviewable record.
NewResearch & IP
Causal Evaluation plan
Choose enough comparison to tell whether a recomposed workflow caused the claimed change.
NewResearch & IP
Cheapest next test
Reduce the most important uncertainty with the least time, money, access, and patient exposure reasonably required.